Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome

Luigi M Larocca1, Paula G Heller2, Gianmarco Podda3

  • 1a Department of Pathology , Policlinico A. Gemelli, Università Cattolica del Sacro Cuore , Rome , Italy .

Platelets
|March 26, 2015
PubMed

Insights

Gray Platelet Syndrome (GPS) patients exhibit impaired platelet function, particularly in response to PAR1 activation, and abnormal megakaryocytes with alpha granule defects. These findings characterize the rare congenital platelet disorder.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Gray Platelet Syndrome (GPS) is a rare inherited bleeding disorder.
  • Characterized by macrothrombocytopenia and absent platelet alpha-granules.
  • Previous studies on platelet and megakaryocyte (MK) defects are limited.

Purpose of the Study:

  • To investigate platelet function and bone marrow (BM) features in GPS patients.
  • To further characterize the molecular and cellular defects in GPS.
  • To correlate NBEAL2 mutations with observed clinical and laboratory findings.

Main Methods:

  • Studied platelet function in five GPS patients with NBEAL2 mutations.
  • Analyzed bone marrow biopsies for cellular morphology and granule content.
  • Utilized immunolabeling for platelet-specific proteins and receptors (e.g., PF4, CD63, P-selectin, PAR1, PAR4, c-MPL).

Main Results:

  • Consistent defect in platelet responses to protease-activated receptor (PAR)1-activating peptide observed.
  • Reduced PAR1 receptors on platelets; normal major glycoprotein expression.
  • Impaired thrombin-induced fibrinogen binding.
  • Bone marrow biopsies revealed fibrosis and extensive emperipolesis in MKs.
  • MKs showed alpha granule-specific defects (reduced PF4, normal CD63).
  • Increased P-selectin and decreased PAR1, PAR4, c-MPL immunolabeling in MKs.

Conclusions:

  • Marked emperipolesis and alpha-granule defects in MKs are characteristic of GPS.
  • Defective PAR1-mediated platelet responses are a consistent finding in GPS.
  • These findings contribute to a deeper understanding and characterization of Gray Platelet Syndrome.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
11.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.9K